Elm Street Ventures

Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Cybrexa, Inc. is focused on developing innovative DNA repair inhibitors aimed at enhancing cancer therapeutics through the use of peptide-based technology that directly targets the tumor microenvironment. Established in 2016 and based in New Haven, Connecticut, the company leverages a unique tumor-localizing peptide technology developed at Yale University. This approach aims to revolutionize drug delivery by improving the therapeutic index, allowing for safer administration of higher doses of chemotherapy and radiotherapy. Cybrexa's pipeline includes a collection of small molecule inhibitors that can be combined with existing anticancer agents, thereby expanding treatment options for patients and addressing significant unmet medical needs in oncology. Through its research, Cybrexa seeks to improve patient outcomes and redefine the landscape of cancer treatment.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.

EvolveImmune Therapeutics specializes in developing innovative immunotherapies aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. The company has created a unique immunobiological platform that enables sustained immune activation and precise targeting of tumor cells through engineered biologics. These first-in-category therapeutics focus on maximizing the therapeutic benefit while minimizing toxicity, setting them apart from conventional CD3 bispecific and other immune therapies. By leveraging a proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates that target various immune cell types, thereby enhancing treatment options for patients suffering from a range of conditions, particularly cancer and autoimmune disorders.

Zid is a cloud-based multi-channel commerce platform tailored for small and medium-sized businesses in Saudi Arabia. Founded in 2017 and headquartered in Riyadh, Zid enables merchants to create their own branded eStores while integrating with various supply chain players. The platform offers a comprehensive suite of tools that allow users to manage products and inventory, process orders and payments, ship products, and build customer relationships. It also provides analytics and reporting features, facilitating data-driven decision-making, and offers access to financing options. Zid's mission is to simplify the entry of retailers into electronic commerce, making it accessible and professional for businesses in the region.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Halda Therapeutics is a research-stage drug discovery company focused on developing next-generation precision medicines. The company utilizes a novel therapeutic modality aimed at creating treatments that can address various disease states. By modifying disease-causing pathways, Halda Therapeutics seeks to enable healthcare providers to offer tailored therapies to patients, enhancing the effectiveness of treatment based on individual patient needs.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

Saphlux, Inc. is a company focused on the development, production, and commercialization of semi-polar gallium nitride (GaN) materials and micro-LED technologies. Founded in 2014 and headquartered in New Haven, Connecticut, Saphlux addresses key issues in the LED and laser industries, such as droop and green gap problems, by offering semi-polar GaN templates in various sizes. Additionally, Saphlux is a pioneer in quantum dot (QD) micro-LED solutions, designing and manufacturing micro-LED chips and micro-display modules for diverse applications, including automotive displays and augmented reality glasses. Their current product offerings include the NPQD R1 chip for public information displays and the NPQD T1 micro-display for AR applications. Operating globally, Saphlux has established a presence in the United States, China, and Japan, aiming to enhance the efficiency and performance of LED products while maintaining competitive pricing.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

SeeClickFix, Inc. is a communications platform designed to facilitate the reporting of non-emergency issues by citizens and enable governments to effectively track, manage, and respond to these reports. The company provides a suite of tools aimed at enhancing transparency, collaboration, and civic engagement within communities. Key offerings include Request Management for efficient data collection and communication, Work Management for managing assignments and internal communication, and Citizen Engagement tools that keep residents informed. Additionally, SeeClickFix offers data analytics solutions to measure success and provide insights for decision-making. The platform is designed to accommodate various community sizes and budgets, thereby empowering citizens and government entities to work together toward improving neighborhoods. Founded in 2007 and based in New Haven, Connecticut, SeeClickFix operates as a subsidiary of CivicPlus, LLC.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Desmos, Inc. is a San Francisco-based company that offers a web-based graphing calculator designed for educational purposes. Founded in 2007 and originally named Tutor Trove, LLC, the company aims to enhance mathematical learning for students and teachers in the United States and internationally. Its platform provides users with the ability to graph functions, plot data tables, evaluate equations, and explore mathematical transformations. By delivering a platform-agnostic software solution, Desmos bridges the gap between different classrooms and facilitates a connection between classroom learning and home study. The interactive graphing platform features a robust math engine that allows users to instantly plot various mathematical equations, making math more accessible and engaging for learners.

Accelerated Orthopedic Technologies, Inc., based in Guilford, Connecticut, specializes in developing proprietary instruments designed to treat articular cartilage defects. The company focuses on creating custom-sized tools that match the specific shapes and topographies required for effective cartilage grafting. Originally incorporated in 2009 under the name Advanced Orthopedic Technologies, the company underwent a rebranding in February 2010 to its current name. With a commitment to innovation, Accelerated Orthopedic Technologies aims to enhance surgical outcomes in orthopedic procedures involving cartilage repair.

Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds. Among the indications under investigation are cancer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.

ShareGrove operates an online conversations platform that enables users to engage with friends from Facebook and other social networks in a dynamic and media-rich environment. The platform allows for both real-time and asynchronous interactions, all managed through a single web interface. Users can enhance their conversations with integrated web searches from sources such as Google, Amazon, and Yelp, which also facilitates revenue generation through affiliate programs. By combining these features, ShareGrove aims to create a seamless and engaging communication experience for its users.

Retail Optimization Inc. specializes in predictive macro optimization analytics aimed at improving profitability in retail environments. The company offers solutions for space management, store remodeling, and assortment planning, enabling retailers and suppliers to identify optimal product selection, category space, and inventory investment. Their software integrates various elements, including consumer insights, supply chain dynamics, market data, and store layouts, to enhance the overall shopping experience for consumers. By leveraging these analytics, retailers can make informed decisions about category, aisle, department, and store size, ultimately driving efficiency and effectiveness in their operations.

Affomix is a biotechnology company specializing in the development of antibody-based products. Utilizing proprietary technology, it offers rapid and automated high-throughput selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, along with mAb microarrays and mAb libraries, for various applications in research, drug discovery, diagnostics, and therapeutics. Affomix aims to enhance the sensitivity and accuracy in measuring large numbers of proteins in biological samples, leveraging its capabilities to produce and screen antibodies against virtually all human proteins, including those that are post-translationally modified.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.